Physician profile
Suresh Malik
NPI 1447466552
$3,416.34
in general payments reported to CMS, 2019-2025
29 companies · $823 in 2025
The $823 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120 · 2021: $413 · 2022: $361 · 2023: $726 · 2024: $972 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $704.56 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $438.02 | 2022-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $388.51 | 2023-2025 | |
| Glaxosmithkline, LLC. | $327.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $154.51 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $136.59 | 2021-2022 | |
| Allergan, INC. | $120.34 | 2019 | |
| Dexcom, INC. | $119.51 | 2023 | Dexcom G6 Transmitter |
| Abbvie INC. | $109.66 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $101.42 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $92.08 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $92.07 | 2021-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.81 | 2022-2024 | Jardiance, Tradjenta, Synjardy |
| Medtronic, INC. | $69.92 | 2024-2025 | Intellis Adaptivestim, Closurefast, Inceptiv |
| Merck Sharp & Dohme LLC | $61.01 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.97 | 2023 | Xifaxan |
| Horizon Therapeutics Plc | $49.93 | 2022 | |
| Irhythm Technologies, INC. | $42.40 | 2024 | Zio Monitor, Zio Xt Patch |
| Bayer Healthcare Pharmaceuticals INC. | $40.18 | 2022-2023 | |
| Inspire Medical Systems, INC. | $34.25 | 2024 | Inspire |
| Corcept Therapeutics | $29.11 | 2024 | Korlym |
| Phathom Pharmaceuticals, INC. | $25.00 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $22.10 | 2022 | |
| Seqirus USA INC | $21.43 | 2025 | Fluad, Flucelvax |
| Calliditas Therapeutics US INC. | $21.29 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.82 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.83 | 2022 | |
| Gilead Sciences, INC. | $16.82 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.13 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suresh Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.